Enovis (NYSE:ENOV) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Key Points

• Enovis beat quarterly estimates, reporting adjusted EPS of $0.90 versus the $0.85 consensus and revenue of $582.8 million versus $581.8 million expected. Revenue rose 3.2% year over year.
• Management reaffirmed 2026 adjusted EPS guidance of $3.52–$3.73, while second-quarter organic sales grew 5% and adjusted EBITDA margin improved to 17.9%.
• Despite improved margins and cash flow, Enovis expects a seasonally weaker third quarter due to softer Western European markets and Middle East disruption; inflation and other costs are projected to reduce full-year results by approximately $10 million.

Enovis (NYSE:ENOV - Get Free Report) released its quarterly earnings data on Thursday. The company reported $0.90 earnings per share for the quarter, topping analysts' consensus estimates of $0.85 by $0.05, FiscalAI reports. The firm had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.During the same quarter in the prior year, the company posted $0.79 earnings per share. The business's quarterly revenue was up 3.2% compared to the same quarter last year. Enovis updated its FY 2026 guidance to 3.520-3.730 EPS.

Here are the key takeaways from Enovis' conference call:

• Second-quarter organic sales grew 5%, led by 6% growth in Recon and 3% in PNR. U.S. Recon hips and knees and extremities each grew 8% in the first half, while Nebula, ARG, and the full commercial launch of ARVIS are gaining traction.
• Adjusted gross margin improved 120 basis points on an underlying basis, and adjusted EBITDA margin rose 70 basis points to 17.9%. Management cited favorable product mix, productivity, and Lima integration synergies, and expects continued multi-year margin expansion.
• Free cash flow improved by $27 million year over year to $31 million in the quarter, bringing first-half cash flow slightly positive. The company reaffirmed its target of greater than 25% free-cash-flow conversion for 2026 and aims to reduce leverage below 3x.
• Enovis reaffirmed its 2026 guidance but expects a seasonally weaker-than-usual third quarter because of softer Western European markets and Middle East-related disruption, followed by sales acceleration in the fourth quarter.
• Inflationary pressure from raw materials, freight, distribution, and the Middle East conflict reduced second-quarter results by $2 million and is expected to total a $10 million full-year impact. Management said passing through additional costs remains difficult, particularly in PNR, because of competitive and market pressures.

Enovis Price Performance

Shares of ENOV stock traded up $0.38 on Friday, reaching $26.68. The company's stock had a trading volume of 2,058,436 shares, compared to its average volume of 1,111,529. The stock's fifty day simple moving average is $24.62 and its 200-day simple moving average is $23.97. Enovis has a 1 year low of $19.14 and a 1 year high of $34.28. The company has a current ratio of 1.98, a quick ratio of 1.05 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of -1.39 and a beta of 1.34.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported second-quarter adjusted earnings of $0.90 per share, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million was also slightly ahead of estimates, while sales increased 3.2% year over year. Enovis Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue of approximately $2.3 billion to $2.4 billion and adjusted EPS guidance of $3.52 to $3.73. Reconstructive sales were a relative bright spot, rising 8% on a reported basis and 6% organically. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, implying substantial potential upside from recent trading levels. BTIG Research Price Target
• Neutral Sentiment: Wells Fargo lowered its price target modestly from $40 to $39 but retained an Overweight rating, indicating continued long-term confidence despite near-term concerns. Wells Fargo Price Target
• Negative Sentiment: The market reaction was negative because Enovis’ second-quarter performance was characterized as “softer than expected.” Although revenue and EPS exceeded published estimates, investors appear focused on the relatively modest 3% reported sales growth and the lack of an upward guidance revision. Enovis Shares Drop After Second-Quarter Earnings
• Negative Sentiment: Enovis continues to report a deeply negative GAAP net margin, which may reinforce investor concerns about profitability and execution even though adjusted earnings improved. Enovis Q2 2026 Earnings Call Transcript

Analyst Upgrades and Downgrades

ENOV has been the topic of a number of research analyst reports. Wells Fargo & Company lowered their price target on Enovis from $40.00 to $39.00 and set an "overweight" rating on the stock in a report on Friday. William Blair initiated coverage on shares of Enovis in a report on Friday, April 17th. They set an "outperform" rating for the company. Wall Street Zen cut shares of Enovis from a "buy" rating to a "hold" rating in a research report on Saturday. Weiss Ratings raised shares of Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 21st. Finally, UBS Group restated a "buy" rating and set a $51.00 target price (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $42.00.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert bought 1,200 shares of Enovis stock in a transaction dated Thursday, June 11th. The shares were purchased at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the acquisition, the insider directly owned 51,840 shares in the company, valued at approximately $1,120,780.80. This represents a 2.37% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Over the last three months, insiders have acquired 4,200 shares of company stock valued at $92,084. Company insiders own 2.90% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP boosted its holdings in Enovis by 1.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company's stock valued at $90,156,000 after acquiring an additional 51,201 shares during the period. Rubric Capital Management LP purchased a new stake in Enovis in the third quarter worth $83,435,000. Paradigm Capital Management Inc. NY increased its stake in Enovis by 41.6% in the second quarter. Paradigm Capital Management Inc. NY now owns 1,113,300 shares of the company's stock worth $34,913,000 after purchasing an additional 326,900 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Enovis by 2.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 951,718 shares of the company's stock worth $25,354,000 after purchasing an additional 24,558 shares during the last quarter. Finally, P2 Capital Partners LLC boosted its stake in shares of Enovis by 87.0% during the second quarter. P2 Capital Partners LLC now owns 617,149 shares of the company's stock valued at $19,354,000 after purchasing an additional 287,149 shares during the period. Institutional investors own 98.45% of the company's stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source